However, our observations regarding the effects of EHMT2 in EGFR-TKI-resistant cells and our finding that EHMT2 positively regulates the AKT pathway, prompted us to evaluate the effectiveness of combination therapy as a treatment for EGFR-TKI-resistant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.